Ingredient or product comparison
Tolerance to GHK-Cu Cycling: Protocol Comparison
Below is a comparison of the three most common cycling protocols for managing tolerance to GHK-Cu in extended research models, drawn from published wound healing, photoaging, and tissue remodeling studies. Continuous with Washout (8 weeks on, 2 weeks off) Dail
This source-based comparison does not add ratings or recommend a winner.
- Below is a comparison of the three most common cycling protocols for managing tolerance to GHK-Cu in extended research models, drawn from published wound healing, photoaging, and tissue remodeling studies.
- Continuous with Washout (8 weeks on, 2 weeks off)
- Daily dosing for 8 weeks, complete cessation for 14 days, repeat
- Begins week 6–8, fully reverses during 2-week washout
- Tissue remodeling endpoints requiring cumulative collagen deposition and sustained gene expression changes
- Requires planned interruptions; not suitable for studies requiring uninterrupted treatment
- Most validated in published dermatology and wound healing research; gold standard for photoaging protocols
- Alternating High/Low Dose (4 weeks high, 2 weeks low)
- 200 mcg daily for 4 weeks, reduce to 50 mcg daily for 2 weeks, repeat
- Partial CTR1 recovery during low-dose phase; full downregulation avoided
- Maintenance of gains after initial loading phase; protocols where complete washout is undesirable
- More complex dosing schedule; low-dose phase efficacy less studied than full washout
- Effective compromise between continuous stimulation and homeostatic adaptation; useful when research timeline prohibits multi-week breaks
- Pulsed Dosing (Every 72–96 hours)
- Single dose every 3–4 days continuously for 8–12 weeks
- Minimal to absent; CTR1 remains stable throughout treatment period
- Signaling studies, long-duration protocols (>12 weeks), models with high baseline copper
- Slower initial response in acute studies; total cumulative dose lower than daily protocols
- Eliminates tolerance entirely but sacrifices speed of initial response; best for studies prioritizing sustained activity over rapid onset